Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BERGEN BRUNSWIG CITES "FAILURE OF SPECIFICITY" IN CALIFORNIA PHARMACY SINGLE-PRICE SUITS AS GROUNDS FOR DISMISSAL, HEARINGS ON MOTIONS SET FOR DEC. 10 & 14

Executive Summary

A federal price discrimination suit brought by California pharmacies under the Robinson-Patman Act should be dismissed because of a "failure of specificity," Bergen Brunswig maintains in court documents filed in the case. The suit, Bacon-Normandi v. Medco Containment, et al., alleges that seven defendants -- Bergen, McKesson, Medco Containment, Bristol-Myers Squibb, Forest, Rhone-Poulenc Rorer and Schering- Plough -- violated federal law by offering deeper discounts to mail-order and other "favored" purchasers of drugs than to retail pharmacy. The suit was filed in San Francisco federal court Aug.12 ("The Pink Sheet" Aug. 16, T&G-3). In an Oct. 22 motion to dismiss, Bergen argues that "plaintiff's pleading in this case consists of nothing more than conclusory allegations of price discrimination." The wholesaler argues that Bacon-Normandi, a Mill Valley, Calif. pharmacy, has not met its obligation to "plead sufficient facts regarding each of the six elements" Bergen believes are required for a Robinson- Patman claim. Specifically, Bergen says, the plaintiff did not: "allege completion of two specific discriminatory sales by each defendant/seller to plaintiff and a specified favored buyer"; allege "contemporaneous sales by any defendant to plaintiff and to a favored buyer"; or "plead that the allegedly discriminatory sales to favored and disfavored buyers involve commodities of like grade and quality." The court filing notes that, while the case had been filed as a class action on behalf of retail pharmacies throughout the U.S., "plaintiff's counsel has advised defense counsel that plaintiff has abandoned its class action allegations." A separate price discrimination suit was filed in Harrisburg, Penn. by pharmacy chains. That suit does not name any wholesalers as defendants ("The Pink Sheet" Oct. 18, p. 10). Bergen's motion is scheduled to be heard by Judge Saundra Brown Armstrong Dec. 14. Bergen Brunswig is being represented by Morrison & Foerster attorneys Melvin Goldman, Lori Schechter and Barbara Reeves. Four other suits were filed by California pharmacies against the same defendants in San Francisco state court charging violations of the state Cartwright Act and Unfair Practices Act. On Oct. 15, Bergen joined with Rhone-Poulenc Rorer in requesting that those proceedings be stayed, again citing the vagueness of the charges. In its Oct. 15 motion, RPR argues that "presumably because any attempt at specificity would reveal the meritless nature of their allegations, plaintiffs have employed a "shotgun" approach to pleading their claims." RPR maintains that it "does not operate sales or production facilities in California, sell directly to any of the named plaintiffs or sell to any of plaintiffs' competitors at discriminatory prices or otherwise." Because the complaints are "impermissibly vague," RPR contends, the four suits should be dismissed. In joining Rhone-Poulenc Rorer's motion to have the cases dismissed, Bergen argues that "the deficiencies in plaintiff's complaint are not mere technicalities, but rather a clear indication of plaintiff's futile attempt to uncover some sort of unlawful conduct in an industry where cost containment concerns have infringed on retail pharmacies' ability to reap high profits. What plaintiff is really complaining about is the rise of companies like Medco, who have successfully implemented cost containment services and fulfilled the demand for pharmaceuticals at lower cost." A hearing on the motion to dismiss the state court cases is slated for Dec. 10, Bergen Brunswig said. Rhone-Poulenc Rorer's attorneys are Mary Cranston, Terrence Callan and Jeffrey Ross of Pillsbury, Madison & Sutro. Plaintiffs in all five cases are being represented by former San Francisco Mayor Joseph Alioto.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS023582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel